Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sint-Niklaas – page 90

1 887 clinical trials in Sint-Niklaas, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Niklaas at a glance
1 887
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 887 trials in Sint-Niklaas

Open in trial search

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine to evaluate immune response and safety in adults 18 years and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Avian influenza

Not recruiting

Study of H5N8 influenza vaccine in adults previously vaccinated with H5N1/MF59 vaccine compared to those never vaccinated with H5 vaccine

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B)
  • Sponsor:University Of Antwerp

Palliative care+1

Not recruiting

Study of testosterone supplementation to improve quality of life in male patients receiving palliative care who have androgen deficiency

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Testosterone decanoate
  • Sponsor:Institut Jules Bordet

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Adenocarcinoma pancreas+2

Not recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Novartis Pharma AG

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Pneumonia viral

Not recruiting

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Interferon BETA-1A
  • Sponsor:Synairgen Research Limited

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Study of MTX-463 compared to placebo to assess its safety and effectiveness in adults with idiopathic pulmonary fibrosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sint-Niklaas

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on lung cancer treatments, including both small cell and non-small cell variants. Multiple trials evaluating novel combination therapies with chemotherapy and immunotherapy agents.

  • Lung Cancer Therapeutics
  • Breast Cancer Treatment
  • Head and Neck Cancer

Studies include evaluation of targeted therapies for specific cancer mutations and biomarkers.

02 Gastroenterology Studies

Clinical investigations focusing on inflammatory bowel conditions, including Crohn's disease and ulcerative colitis. Trials evaluating new therapeutic approaches for disease management.

  • Inflammatory Bowel Disease
  • Hepatitis Treatment
  • Disease Activity Assessment

Research emphasizes both therapeutic intervention and disease monitoring strategies.

03 Cardiovascular Research

Studies examining treatments for coronary artery disease and stroke prevention in patients with atrial fibrillation. Trials evaluating novel anticoagulation approaches.

  • Stroke Prevention
  • Post-PCI Treatment
  • Cardiac Therapeutics

Focus on both preventive measures and post-intervention care strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.